Establishment of Automated Point-of-Care Manufacturing of ΔNPM1 TCR-Engineered T Cells for AML Therapy

被引：0
|
作者：
Ogusuku, Isabella Elias Yonezawa [1 ]
Agiro, Eva [2 ]
Herbel, Vera [1 ]
Brandes, Caroline [1 ]
Veld, Sabrina [2 ]
Hageman, Lois [2 ]
Griffioen, Marieke [2 ]
Schaser, Thomas [1 ]
de Groot, Rosa [2 ]
Lock, Dominik [1 ]
Johnston, Ian C. D. [1 ]
机构：
[1] Miltenyi Biotec BV & Co KG, Bergisch Gladbach, Germany
[2] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands
来源：
MOLECULAR THERAPY | 2024年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
286
引用
收藏
页码：153 / 154
页数：2
相关论文
共 38 条
  • [31] A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CART-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma
    Shah, Nirav N.
    Zhu, Fenlu
    Taylor, Carolyn
    Schneider, Dina
    Krueger, Winfried
    Worden, Andrew
    Yim, Sharon
    Fenske, Timothy S.
    Hamadani, Mehdi
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    BLOOD, 2018, 132
  • [32] Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Flexibility for a Phase I Clinical Trial in Relapsed, Refractory NHL
    Zhu, Fenlu
    Shah, Nirav N.
    Schneider, Dina
    Xu, Huiqing
    Chaney, Katherine
    Luib, Lawrence
    Keever-Taylor, Carolyn A.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    Johnson, Bryon
    BLOOD, 2018, 132
  • [33] IMMUNE THERAPY FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): DEVELOPMENT OF A GOOD MANUFACTURING PRACTICE (GMP) CONFORM PROTOCOL BASED ON WILMS' TUMOR 1(WT1)-SPECIFIC CYTOTOXIC T CELLS (CTL)
    Hermann, Eugenie
    Horn, Peter A.
    Lindemann, Monika
    Ottinger, Hellmut
    Beelen, Dietrich W.
    Buttkereit, Ulrike
    ANNALS OF HEMATOLOGY, 2013, 92 : S14 - S15
  • [34] Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial
    Kersten, Marie Jose
    Saevels, Kirsten
    Beguin, Yves
    Vermaat, Joost S. P.
    Verbruggen, Nadia
    Spoon, Maike
    Liefaard, Marte C.
    Pont, Margot
    van Muyden, Anna D. D.
    Kuipers, Maria T.
    Anguille, Sebastien
    BLOOD, 2023, 142
  • [35] Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
    Tovar, Natalia
    Ortiz-Maldonado, Valentin
    Martinez-Cibrian, Nuria
    Betriu, Sergi
    Esteban, Daniel
    Triguero, Ana
    Verbruggen, Nadia
    Spoon, Maike
    Liefaard, Marte C.
    Pont, Margot
    van Muyden, Anna D. D.
    BLOOD, 2023, 142
  • [36] EUPLAGIA-1: SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE MANUFACTURED GLPG5201 ANTI-CD19 CAR-T CELLS DISPLAY EARLY PHENOTYPES IN RELAPSED/REFRACTORY CLL INCLUDING RT
    Hoefsmit, Esmee P.
    Blum, Sandra
    Vennin, Claire
    Van Hoorde, Kirsten
    Betriu, Sergi
    Alserawan, Leticia
    Delgado, Julio
    Verbruggen, Nadia
    van Muyden, Anna D. D.
    Rozema, Henriette
    Astigarraga, Ruiz
    Pont, Margot J.
    BONE MARROW TRANSPLANTATION, 2024, 59 : 201 - 202
  • [37] DEVELOPING THERAPY FOR ACUTE MYELOID LEUKEMIA WITH FIVE-GENE ENGINEERED T-CELLS EXPRESSING TRANSGENIC WT-1 TCR, GM-CSF LIGAND-BASED CAR, CD3X33 BITE AND EGFR SUICIDE GENE SYSTEM
    Smilauerova, K.
    Otahal, P.
    Mucha, M.
    Stach, M.
    Vanikova, S.
    Musil, J.
    HUMAN GENE THERAPY, 2023, 34 (21-22) : A23 - A24
  • [38] Clinical Results of a First-in-Human Phase 1 Study of Point-of-Care Manufactured Bispecific Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-20.19-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma (NHL)
    Shah, Nirav N.
    Zhu, Fenlu
    Keever-Taylor, Carolyn
    Schneider, Dina
    Kruger, Winfred
    Worden, Andrew
    Hamadani, Mehdi
    Fenske, Timothy S.
    Johnson, Bryon D.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
1234